Granted Patent B2

US 12,263,161 · App. 18/415,196 · Granted Apr 1, 2025

Inventor: Herriot Tabuteau (New York, NY)

Assignee: ANTECIP BIOVENTURES II LLC

A61K31/485A61K9/2027A61K9/2086A61K31/138

Abstract

Claims (24)

1. A method of treating agitation associated with Alzheimer's disease in a human patient who is consuming alcohol, comprising administering, twice a day, a dosage form to a human patient for the treatment of agitation associated with the patient's Alzheimer's disease, and reducing but not discontinuing consumption of alcohol by the human patient, wherein the dosage form comprises 105 mg of bupropion hydrochloride, or a molar equivalent amount of another salt form of bupropion or the free base form of bupropion, 45 mg of dextromethorphan hydrobromide, or a molar equivalent amount of another salt form of dextromethorphan or the free base form of dextromethorphan, and a polymer.

2. The method of claim 1 , wherein the human patient is an adult male, and the human patient consumes two servings or less of alcohol per day.

3. The method of claim 1 , wherein the human patient is an adult female, and the human patient consumes one serving or less of alcohol per day.

4. The method of claim 1 , wherein the dosage form further comprises: colloidal silicon dioxide, crospovidone, glyceryl monocaprylocaprate, L-cysteine hydrochloride monohydrate, magnesium stearate, microcrystalline cellulose, polyvinyl alcohol, red iron oxide, sodium lauryl sulfate, stearic acid, talc, titanium dioxide, or yellow iron oxide, or a combination thereof.

5. The method of claim 1 , wherein the polymer is a carbomer homopolymer.

6. A method of treating agitation associated with Alzheimer's disease in a human patient who is consuming alcohol, comprising administering, twice a day, a dosage form to a human patient for the treatment of agitation associated with the patient's Alzheimer's disease, and minimizing but not discontinuing consumption of alcohol by the human patient, wherein the dosage form comprises 105 mg of bupropion hydrochloride, or a molar equivalent amount of another salt form of bupropion or the free base form of bupropion, 45 mg of dextromethorphan hydrobromide, or a molar equivalent amount of another salt form of dextromethorphan or the free base form of dextromethorphan, and a polymer.

7. The method of claim 6 , wherein the dosage form further comprises: colloidal silicon dioxide, crospovidone, glyceryl monocaprylocaprate, L-cysteine hydrochloride monohydrate, magnesium stearate, microcrystalline cellulose, polyvinyl alcohol, red iron oxide, sodium lauryl sulfate, stearic acid, talc, titanium dioxide, or yellow iron oxide, or a combination thereof.

8. The method of claim 6 , wherein the human patient is an adult male, and the human patient consumes two servings or less of alcohol per day.

9. The method of claim 6 , wherein the human patient is an adult female, and the human patient consumes one serving or less of alcohol per day.

10. The method of claim 6 , wherein the polymer is a carbomer homopolymer.

11. A method of treating agitation associated with Alzheimer's disease in an adult human patient who is consuming alcohol, comprising administering, twice a day, a dosage form to a human patient for the treatment of agitation associated with the patient's Alzheimer's disease, wherein the dosage form comprises 105 mg of bupropion hydrochloride, or a molar equivalent amount of another salt form of bupropion or the free base form of bupropion, 45 mg of dextromethorphan hydrobromide, or a molar equivalent amount of another salt form of dextromethorphan or the free base form of dextromethorphan, and a polymer,

wherein if the human patient is a male, the human patient is consuming two servings or less of alcohol per day; and

if the human patient is a female, the human patient is consuming one serving or less of alcohol per day.

12. The method of claim 11 , wherein the dosage form further comprises colloidal silicon dioxide.

13. The method of claim 11 , wherein the dosage form further comprises crospovidone.

14. The method of claim 11 , wherein the dosage form further comprises glyceryl monocaprylocaprate.

15. The method of claim 11 , wherein the dosage form further comprises L-cysteine hydrochloride monohydrate.

16. The method of claim 11 , wherein the dosage form further comprises magnesium stearate.

17. The method of claim 11 , wherein the dosage form further comprises microcrystalline cellulose.

18. The method of claim 11 , wherein the dosage form further comprises polyvinyl alcohol.

19. The method of claim 11 , wherein the dosage form further comprises sodium lauryl sulfate.

20. The method of claim 11 , wherein the dosage form further comprises stearic acid.

21. The method of claim 11 , wherein the dosage form further comprises titanium dioxide.

22. The method of claim 11 , wherein the polymer is a carbomer homopolymer.

Assignments (1)

Continuity (6)

References Cited (400)

Cited By (14)

US 12,433,884 US 12,447,138 US 12,472,155 US 12,472,156 US 12,472,174 US 12,478,622 US 12,544,345 US 12,564,587 US 12,569,479 US 12,576,078 US 12,599,576 US 12,653,795 US 12,661,408 US 12,678,506